-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
AG-1478
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/153436-53-4.gif)
| Category | Influenza Virus |
| CAS | 153436-53-4 |
| Description | AG-1478 (NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM; almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. |
Product Information
| Synonyms | Tyrphostin AG-1478; AG-1478; AG1478; AG 1478 |
| IUPAC Name | N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine |
| Molecular Weight | 315.75 |
| Molecular Formula | C16H14ClN3O2 |
| Canonical SMILES | COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC |
| InChI | InChI=1S/C16H14ClN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20) |
| InChIKey | GFNNBHLJANVSQV-UHFFFAOYSA-N |
| Boiling Point | 458.5±45.0 °C at 760 mmHg |
| Melting Point | 247 °C(dec.) |
| Flash Point | 231.1±28.7 °C |
| Purity | >98% |
| Density | 1.3±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : 50mg/mL(158.35mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (6.59 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (6.59 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (6.59 mM); Clear solution 4.Add each solvent one by one:1% CMC0.5%Tween-80 Solubility: 5 mg/mL (15.84 mM); Suspended solution; Need ultrasonic |
| Appearance | White to off-white (Solid) |
| Application | Enzyme Inhibitors |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Animal Admin | 28 C57BL/6 or ApoE-/- mice are randomly divided into four weight-matched groups. From week 9, AG-1478 or 542 is administered daily by oral gavage at a dose of 10 mg / kg / day for the next 8 weeks. AG-1478 and dendritic polymer treatment are administered at a single dose for 24 h before execution. An automated blood glucose analyzer is used to assess blood glucose concentrations, and rats with blood glucose concentrations above 250 mg/dL (approximately 14 mM) have been declared diabetic. |
| Assay | DU145 (HTB-81) and A549 (CCL-185) cells are seeded in MEM (DU145 cells) or DMEM (A549 cells) on a 96-well plate, supplemented with 100 IU/mL penicillin in the presence of 10% FBS, 100 μg/mL streptomycin. AG494, AG-1478, concentration ranges of 1-20 μM and 0.1-8 μM, respectively. Modified crystal violet staining (CV) and MTT methods were used to determine the effect of tyrphostins on target cell proliferation. |
| Complexity | 360 |
| Exact Mass | 315.077454 |
| Index Of Refraction | 1.668 |
| In Vitro | AG-1478 (AG1478) is irreversible for the growth regulation of human lung (A549) and prostate (DU145) cancer cell lines. Inhibition of EGFR by the specific tyrosine kinase inhibitor AG-1478 (AG1478) significantly reduces the synthesis of TGF-β and fibronectin by angiotensin-II-mediated cardiac fibroblasts. |
| In Vivo | The administration of AG-1478 (AG1478) significantly reduced myocardial inflammation, fibrosis, Apoptosis, and dysfunction in two obese mouse models. |
| PSA | 56.27000 |
| Target | EGFR; HCV; Influenza Virus |
| Vapor Pressure | 0.0±1.1 mmHg at 25°C |
| XLogP3-AA | 4 |
